Two drug makers — Aimmune Therapeutics (AIMT) and AnaptysBio (ANAB) — are developing different methods to protect people against severe peanut allergy and will disclose important clinical trial results within the next two months.

Anyone with school-age children knows peanut allergy is a serious and prevalent health problem. It’s estimated that between 1.5 million to 2 million people under 18 in the U.S. have peanut allergy. Apart from scrupulous peanut avoidance, there are no approved treatments for people at risk for severe allergic reaction if exposed to even trace amounts of peanut protein.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • You wrote that in the “Phase 2 study conducted by Aimmune, 62 percent of people dosed with AR101 were able to tolerate a 600 mg peanut protein food challenge after six months compared to zero patients in a placebo arm. The biostatistical separation between the two arms of the Phase 2 study favored AR101 by 37 percent”

    I’m confused how 62% became 37%. Did they explain the math?

  • You referenced parents with school-aged children…
    Both companies are attempting to treat peanut allergies by different approaches, for different patient populations. AIMT is target 4-17 year-olds with AR-101 desensitization. Immunomodualting drugs such as ANAB’s ANB020 are for adults only.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy